Cell Biotech Reports Operating Profit of 3.6 Billion KRW in First Half... "Successful Turnaround to Profit"

Cell Biotech, a leading microbiome company in South Korea, has succeeded in turning its operating profit positive in the first half of the year.

On the 6th, Cell Biotech announced that it recorded provisional results of 25.6 billion KRW in cumulative sales, 3.6 billion KRW in operating profit, and 7.3 billion KRW in net profit for the first half of the year. Compared to the same period last year, sales increased by 1.2%, operating profit turned positive, and net profit increased by 1,048%.

Cell Biotech explained that it succeeded in turning operating profit positive due to a significant increase in highly profitable exports based on product competitiveness.

Famous for its ‘DUOLAC’ brand, Cell Biotech exports Korean-made probiotics to 55 countries worldwide, including Denmark, the probiotic pioneer country, based on the excellence and safety of Korean probiotics.

In February this year, the company achieved the remarkable feat of registering 11 types of Korean probiotics, the most in the world, under the ‘FDA GRAS (Generally Recognized As Safe)’, the highest safety verification system recognized globally.

In addition, Cell Biotech is leading the globalization of K-probiotics based on world-class probiotic development technology, 29 years of probiotic manufacturing know-how, and international certifications such as Halal and Kosher, including the development of the colorectal cancer new drug ‘PP-P8’ using Korean probiotics. PP-P8 is an oral anticancer drug and an innovative new drug (FIRST-IN-CLASS) developed using synthetic biology technology, which is completely different from existing drugs.

Lee Sang-hoon, Director of the Management Strategy Division at Cell Biotech, said, "Cell Biotech complies with global standard criteria to produce safer products and has strong competitiveness in the global probiotic market with achievements such as the world’s highest number of FDA GRAS registrations. Despite unstable international conditions, exports centered on Asia and Europe increased, leading to an improvement in operating profit.”